Therapeutic Area
Drug: Indication (Target)
Preclinical
Phase I
Phase II
Phase III
Anticipated Milestones
Anticipated Milestones
Report Top-Line CLASSIC Trial Results in mid 2016

Initiate Phase III in AAV by end of 2016

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones
Conduct EOP2 Meeting
Anticipated Milestones
Report Early Results from Pancreatic Cancer Trial H1 2016 and initial PFS results in 2H 2016
Drug: Indication (Target)
Pre
PI
PII
PIII
CCX354: Rheumatoid Arthritis/Myeloma Bone Metastasis (CCR1)
Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

CCR1 CCX354 Completed Phase IIa

Progress in TH17 Disease

* also known as CCX282 or Traficet-EN.